一、主要会计数据和财务指标 | 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | -2.1700 | -2.5000 | 13.2 | -2.1000 | | 每股净资产（元） | 5.8 | 7.59 | -23.58 | 0.11 | | 每股公积金(元) | 11.43 | 11.01 | 3.81 | 2.08 | | 每股未分配利润(元) | -6.59 | -4.42 | -49.1 | -2.98 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 0.3 | 0.01 | 2900 | 0 | | 净利润(亿元) | -7.97 | -8.01 | 0.5 | -5.76 | | 净资产收益率(%) | -32.65 | -57.87 | 43.58 | -337.99 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 3708.75万股，累计占流通股比： 32 ...

国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 2024 年度持续督导工作现场检查报告 上海证券交易所： 国泰海通证券股份有限公司（以下简称"国泰海通"、"保荐人"）作为重庆 智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"）首次公开 发行股票并在科创板上市的保荐人，根据《中华人民共和国公司法》《中华人民 共和国证券法》《证券发行上市保荐业务管理办法》《上海证券交易所科创板股票 上市规则》（以下简称"《上市规则》"）和《上海证券交易所上市公司自律监管指 引第 11 号——持续督导》等有关法律法规的规定，对公司 2024 年度（以下简称 "本持续督导期间"）的规范运作情况进行了现场检查，现就现场检查的有关情 况报告如下： 一、本次现场检查的基本情况 （一）保荐人 国泰海通证券股份有限公司 （二）保荐代表人 王永杰、刘丹 （三）现场检查时间 2025 年 4 月 9 日至 2025 年 4 月 12 日 （四）现场检查人员 王永杰、刘丹 （五）现场检查内容 现场检查人员对本持续督导期内发行人公司治理及内部控制、信息披露、独 立性、与关联方的资金往来、募集资金使用情况、关联交易、对外担保 ...

Core Viewpoint - The article discusses the recent performance of the STAR Market Composite Index and highlights the impact of U.S.-China trade policies on the pharmaceutical sector, suggesting potential investment opportunities in innovation, overseas markets, equipment upgrades, and consumer recovery [3][4]. Group 1: Market Performance - As of April 14, 2025, the STAR Market Composite Index rose by 1.13%, with notable increases in stocks such as Yuyuan Pharmaceutical (up 19.99%) and Kexing Pharmaceutical (up 17.23%) [3]. - The STAR Market ETF (Hua Xia) also saw a rise of 1.19%, marking its fifth consecutive increase, with a latest price of 0.94 yuan [3]. - The trading volume for the STAR Market ETF was active, with a turnover rate of 23.24% and a transaction value of 197 million yuan [3]. Group 2: Trade Policy Impact - Following the U.S. government's announcement of a 34% tariff on Chinese goods on April 2, 2025, both countries adjusted their bilateral trade tariffs to 125% as of April 11, 2025 [3]. - The frequent adjustments in tariff policies are expected to disrupt U.S.-China pharmaceutical trade, but companies primarily exporting to markets outside the U.S. may be less affected [3]. - The increased tariffs on U.S. goods could accelerate the import substitution process for high-market-share biopharmaceutical products in China [3]. Group 3: Investment Themes - The report suggests focusing on "innovation," "overseas expansion," "equipment upgrades," and "consumer recovery" as key investment themes [4]. - The "innovation" theme emphasizes investing in globally competitive innovative drugs and promising categories with significant market potential [4]. - The "overseas expansion" theme indicates that there are long-term opportunities in overseas markets [4]. - The "equipment upgrades" theme anticipates increased support for medical equipment updates from central and local government financing [4]. - The "consumer recovery" theme highlights potential rebounds in sectors like ophthalmology, dentistry, and medical aesthetics due to consumer stimulus policies [4]. Group 4: ETF Performance and Metrics - The STAR Market ETF (Hua Xia) has reached a new high in scale at 839 million yuan and a new high in shares at 908 million [4]. - Recent net inflows into the ETF totaled approximately 22.08 million yuan, with a total of 57.84 million yuan net inflow over the past five trading days [4]. - The ETF's management fee is 0.15%, and the custody fee is 0.05%, which are among the lowest in comparable funds [5]. - The tracking error for the ETF over the past month is 0.010%, indicating high tracking precision compared to similar funds [5]. Group 5: Valuation Insights - The latest price-to-earnings ratio (PE-TTM) for the STAR Market Composite Index is 129.12, which is at a historical low, being in the 19.67th percentile over the past year [6]. - The top ten weighted stocks in the STAR Market Composite Index account for 22.34% of the index, with companies like Haiguang Information and Cambricon Technologies among the leaders [6].

证券代码：688443 证券简称：智翔金泰 公告编号：2025-009 重庆智翔金泰生物制药股份有限公司 关于股份回购进展公告 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》的相关规定，公司在回购期间，应当在每个月的前 3 个交易日内 公告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 3 月 31 日，公司已通过上海证券交易所交易系统以集中竞价交 易方式累计回购公司股份 759,800 股，占公司总股本 366,680,000 股的比例为 0.2072%，回购成交的最高价为 28.257 元/股，最低价为 22.89 元/股，支付的资金 总额为人民币 19,368,205.27 元（不含佣金、过户费等交易费用）。 本次回购股份符合法律法规的规定及公司回购股份方案。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 ...

智翔金泰 20250312 摘要 Q&A 浙江银泰在自免领域的布局和进展如何？ 自免领域是全球范围内仅次于肿瘤的第二大治疗领域，浙江银泰在这一领域有 着全面的靶点和适应症布局。白介素-17、TH17、白介素-23 等细胞轴在银屑病 致病机理方面相对清晰，生物制剂处于核心位置。根据 2022 年下半年到 2023 年上半年的统计，美国市场上银屑病治疗领域 90%以上的销售额由天赋阿尔法、 百加 23 和百介 17 这三个靶点贡献，其余 10%则由 PDE4 和 Tik2 的小分子口服 制剂贡献。生物制剂从最早的 TNFα到最新一代产品，如 apple 位的瑞杀猪， • 美国银屑病治疗市场高度集中，90%以上销售额由 TNFα、白介素 23 和白 介素 17 三个靶点生物制剂贡献，疗效随产品迭代不断提升，从 PC50 到 PC90。 • 国内银屑病生物制剂市场竞争激烈，诺华可善挺因价格优势占据较高市场 份额。目前已上市十款生物制剂，浙江银泰与恒瑞国产白介素 17A 产品预 计在医保谈判后迎来销售放量。 • 白介素-4 通路药物市场潜力巨大，赛诺菲达必妥销售额领先。国内赛诺菲 与康诺亚已上市相关药物，多家企业的三期 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 651,207 股 | | 累计已回购股数占总股本比例 | 0.1776% | | 累计已回购金额 | 元 16,797,393.41 | | 实际回购价格区间 | 23.23 元/股~28.257 元/股 | 证券代码：688443 证券简称：智翔金泰 公告编号：2025-008 重庆智翔金泰生物制药股份有限公司 关于股份回购进展公告 重庆智翔金泰生物制药股份有限公司董事会 一、 回购股份的基本情况 购股份的方案》（公告编号 2024-034）。 本次回购股份符合法律法规的规定及公司回购股份方案。 ...

Financial Performance - Total revenue for 2024 reached RMB 30,094,960.63, a significant increase of 2384.10% compared to RMB 1,211,502.42 in the previous year[3] - The company reported a net loss attributable to shareholders of RMB 800,449,029.93, a slight improvement of 0.11% from the previous year's loss of RMB 801,319,298.24[3] - Basic earnings per share decreased to -RMB 2.18, down 12.80% from -RMB 2.50 in the prior year[3] - The company's total assets decreased by 12.49% to RMB 3,145,716,912.53 from RMB 3,594,596,738.24 at the beginning of the period[3] - Shareholders' equity attributable to the parent company fell by 23.75% to RMB 2,122,867,387.53 from RMB 2,784,232,358.39[3] - The weighted average return on net assets improved by 25.07 basis points to -32.80% from -57.87%[3] Research and Development - The company maintained a high level of R&D investment as multiple products entered clinical research and key clinical trial phases[5] - The significant increase in revenue was primarily due to the approval and sales of the product "赛立奇单抗注射液" (金立希®), which was not present in the previous year's revenue[5] Audit and Caution - The company emphasizes that the financial data is preliminary and subject to final audit in the annual report[6] - Investors are advised to be cautious as the reported figures are not yet audited and may be subject to change[6]

重庆智翔金泰生物制药股份有限公司 自愿披露关于GR1802注射液启动慢性自发性荨麻疹 适应症III期临床试验的公告 证券代码：688443 证券简称：智翔金泰 公告编号：2025-006 GR1802 注射液已获得多个适应症的临床试验批准通知书。继中、重度特应 性皮炎适应症、慢性鼻窦炎伴鼻息肉适应症进入Ⅲ期临床试验后，慢性自发性荨 麻疹适应症也将正式启动 III 期临床试验。过敏性鼻炎和哮喘适应症均处于 II 期 临床试验阶段，儿童/青少年特应性皮炎适应症处于Ⅰb/II 期临床试验阶段。 截至本公告披露日，GR1802 注射液同靶点药物仅有两款在国内获批上市。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，重庆智翔金泰生物制药股份有限公司（以下简称"公司"）就"一项 评价 GR1802 注射液在慢性自发性荨麻疹患者中的有效性、安全性和免疫原性的 随机、双盲、安慰剂对照、多中心 III 期临床试验"的开展，完成与国家药品监 督管理局药品审评中心（CDE）EOP2（II 期临床试验结束/III 期临床试验启动前） 的会议沟 ...

购股份的方案》（公告编号 2024-034）。 二、 回购股份的进展情况 证券代码：688443 证券简称：智翔金泰 公告编号：2025-005 重庆智翔金泰生物制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | --- | --- | | 回购方案实施期限 | 董事会审议通过后 个月 12 | | 预计回购金额 | 2,000 万元~4,000 万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 645,907 股 | | 累计已回购股数占总股本比例 | 0.1762% | | 累计已回购金额 | 元 16,674,274.41 | | 实际回购价格区间 | 元/股~28.257 元/股 24.33 | 一、 回购股份的基本情况 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2024 ...

Revenue Expectations - The company expects 2024 annual revenue to be between 28.62 million and 31.64 million, an increase of 27.41 million to 30.43 million compared to the previous year, representing a year-on-year growth of 2262.72% to 2511.43%[2] - The significant revenue growth is primarily due to the commercial launch of the company's monoclonal antibody injection, which generated sales revenue, whereas the previous year had minimal revenue from technical services[6] R&D Expenses - The estimated R&D expenses for 2024 are projected to be between 560.48 million and 657.96 million, a decrease of 59.91 million to an increase of 37.56 million compared to the previous year, reflecting a year-on-year change of -9.66% to +6.05%[2] - The company maintains a high level of R&D investment as multiple products enter clinical research and core products reach critical clinical trial stages[6] Net Loss Projections - The expected net loss attributable to the parent company for 2024 is projected to be between -731.28 million and -858.46 million, a reduction of 70.04 million to an increase of 57.14 million compared to the previous year, indicating a year-on-year change of -8.74% to +7.13%[2] - The net loss attributable to the parent company after deducting non-recurring gains and losses is expected to be between -738.34 million and -865.52 million, with a year-on-year change of -9.18% to +6.47%[3] Financial Forecast Integrity - The financial data in this earnings forecast is based on preliminary calculations by the company's finance department and has not been audited by a registered accountant[7] - The company has not identified any major uncertainties that could affect the accuracy of this earnings forecast[7]